It is over 4 years since the Prospective Comparison of ARNI (angiotensin receptor/neprilysin inhibitor—editor’s note) with ACEI (angiotensin-converting enzyme inhibitor—editor’s note) to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial was published in New England Journal of Medicine. This evidence concerns the gene MME and hydrops fetalis.